Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KYMR Kymera Therapeutics, Inc.

Trading 04-02 11:30:12 EDT

26.50

+1.27

+5.01%

High26.68	Low24.43	Vol199.52K
Open24.81	D1 Closing25.24	Amplitude8.90%
Mkt Cap1.72B	Tradable Cap1.14B	Total Shares64.94M
T/O5.17M	T/O Rate0.47%	Tradable Shares42.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"KYMR","market":"US","secType":"STK","nameCN":"Kymera Therapeutics, Inc.","latestPrice":26.5,"timestamp":1743607774653,"preClose":25.235,"halted":0,"volume":199517,"delay":0,"floatShares":42841165,"shares":64944136,"eps":-2.983023,"marketStatus":"Trading","change":1.265,"latestTime":"04-02 11:30:12 EDT","open":24.81,"high":26.675,"low":24.43,"amount":5167057.34811,"amplitude":0.088964,"askPrice":26.5,"askSize":1,"bidPrice":26.43,"bidSize":462,"shortable":0,"etf":0,"ttmEps":-2.983023,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743624000000},"marketStatusCode":2,"adr":0,"listingDate":1597982400000,"exchange":"NASDAQ","adjPreClose":25.235,"preHourTrading":{"tag":"盘前","latestPrice":26.9575,"preClose":25.235,"latestTime":"08:00 EDT","volume":75,"amount":1996.2970500000001,"timestamp":1743595202592},"postHourTrading":{"tag":"盘后","latestPrice":25.235,"preClose":25.235,"latestTime":"18:49 EDT","volume":2429,"amount":61307.48,"timestamp":1743547798803},"volumeRatio":0.92385,"impliedVol":1.1917,"impliedVolPercentile":0.9801},"requestUrl":"/m/hq/s/KYMR","defaultTab":"news","newsList":[{"id":"2520195421","title":"Top Analyst Reports for Shell, Uber & TotalEnergies","url":"https://stock-news.laohu8.com/highlight/detail?id=2520195421","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520195421?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 06:31","pubTimestamp":1742423460,"startTime":"0","endTime":"0","summary":"Wednesday, March 19, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Shell plc (S","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-analyst-reports-shell-uber-223100107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2129689605.HKD","PEG","ATGE","TTE","BK4566","LU0320765646.SGD","LU0444973449.USD","IE00BMG7P819.SGD","SHEL","LU0353189763.USD","BK4084","PRM","LU2210149790.SGD","IRDM","FMS","LU2210150020.SGD","BK4183","LU2264538146.SGD","EVR","LU2491049909.HKD","DD","GEOS","RARE","IE00B19Z3581.USD","BK4503","GDDY","SG9999017495.SGD","BK4107","LU0353189680.USD","DECK","BK4504","KYMR","LU1162221912.USD","CCI","LU0654597011.USD","BK4117","LU0098860793.USD","BK4528","BK4230","IE00BMG7P694.USD","BK4196","UBER","AFG","SG9999014898.SGD","NHTC","BK4017","BK4567","WPM","LU0266013472.USD","LU2517655028.SGD"],"gpt_icon":0},{"id":"2519856750","title":"BUZZ-U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTx","url":"https://stock-news.laohu8.com/highlight/detail?id=2519856750","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519856750?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 23:47","pubTimestamp":1741880850,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTxEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW19Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0162691827.USD","NEM","ATEN","LU2065169927.USD","PCAR","AEO","MNTK","BBW","ETNB","LU1043141123.HKD","IE00BMPRXQ63.HKD","TARS","KNSA","LU2506952170.USD","MGTX","AVAH","DLTR","NVAX","LU0276348264.USD","ALKT","FOSL","LU2498475776.HKD","LU2430703178.SGD","GIII","SPIR","AEYE","IE00BJJMRX11.SGD","LYV","LU0096364046.USD","NN","LU2250418816.HKD","LU2317271919.USD","LU0238689110.USD","MCB","APGE","BK4570","KYMR","TRIB","NOVA","LU1496350171.SGD"],"gpt_icon":1},{"id":"2519393418","title":"BUZZ-Citigroup starts coverage of Kymera with $52 PT","url":"https://stock-news.laohu8.com/highlight/detail?id=2519393418","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519393418?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 20:40","pubTimestamp":1741869647,"startTime":"0","endTime":"0","summary":"BUZZ-Citigroup starts coverage of Kymera with $52 PT** Citigroup starts coverage of Kymera Therapeutics' KYMR.O shares with \"buy/high risk\" rating and $52 PT, a ~48% upside to stock's last close** Brokerage says company's targeted protein degradation technology offers \"first-in-class\" approaches in the treatment of various inflammatory and immunological diseases** Company's atopic dermatitis drug KT-621 has shown \"robust preclinical data\" with potential to achieve \"comparable or superior efficacy\" to Regeneron REGN.O and Sanofi's SASY.PA  Dupixent, Citigroup says** Kymera's inflammatory skin disease drug KT-474 has shown promising data in clinical trials, particularly in hidradenitis suppurativa, where it demonstrated a \"remarkable ~60% reduction in symptoms\", positioning it as a potential \"best-in-class\" therapy - brokerage** Brokerage estimates company's revenue to reach $1 bln by 2032, with each additional $500 bln in sales potentially adding $20 to the stock price** Kymera's shares","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW0YV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU2362541513.USD","LU2237438978.USD","LU2468319806.SGD","BK4588","LU0109394709.USD","LU0289739699.SGD","REGN","LU0058720904.USD","LU0882574055.USD","LU0320765992.SGD","LU2023250504.SGD","LU2089984988.USD","KYMR","BK4585","LU0889565916.HKD","BK4139","LU2106854487.HKD","LU1974910355.USD","LU0114720955.EUR","LU2362541273.HKD","LU0053666078.USD","LU2362540622.SGD","LU1917777945.USD"],"gpt_icon":0},{"id":"2519880301","title":"Citigroup Initiates Coverage on Kymera Therapeutics With Buy Rating, $52 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2519880301","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519880301?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 19:13","pubTimestamp":1741864412,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics (KYMR) has an average rating of Buy and mean price target of $58.82, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KYMR","LENZ"],"gpt_icon":0},{"id":"2519878538","title":"BUZZ-Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=2519878538","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519878538?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 18:56","pubTimestamp":1741863404,"startTime":"0","endTime":"0","summary":"BUZZ-Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty   ** Brokerage Citi initiates coverage on eight small and mid-cap  biotechs - 89bio ETNB.O, Apogee Therapeutics APGE.O, Avidity Biosciences RNA.O, BioNTech 22UAy.DE, Kiniksa Pharmaceuticals KNSA.O, Kymera Therapeutics KYMR.O, Moderna MRNA.O and PTC Therapeutics PTCT.O** Citi suggests SMid biotechs could be a good alternative to larger-cap stocks amid healthcare policy uncertainty** Recent economic uncertainties, including increased tariffs and slowing economic growth, have \"underscored the defensive attributes\" of biotech and pharma stocks, brokerage says ** Higher-growth large caps such as Eli Lilly LLY.N and Vertex Pharma VRTX.O are likely able to absorb potential policy headwinds and \"catalyst-driven\" SMid biotechs are \"insulated from macro uncertainties\" - Citi** YTD, S&P500 Health Care index .SPXHC has grown ~5%, NYSE Arca Pharmaceutical Index .DRG has gained ~6% and NASDAQ Biotechnology Inde","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW0SW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTCT","LU2063271972.USD","LU2237443978.SGD","ETNB","SG9999017495.SGD","LU2265009873.SGD","LU1291159041.SGD","MRNA","LU2362541513.USD","LU1064131342.USD","BK4007","LU0106261372.USD","LU1868837300.USD","LU1868836591.USD","LU2023250504.SGD","LU1551013342.USD","RNA","APGE","SG9999018865.SGD","SGXZ81514606.USD","IE00BFTCPJ56.SGD","IE00B19Z3B42.SGD","LU1917777945.USD","LU2211815571.USD","LU0109391861.USD","IE0002141913.USD","IE00BJLML261.HKD","KNSA","LU0061475181.USD","LU1093756325.SGD","LU0417517546.SGD","VRTX","LU0097036916.USD","LU0096364046.USD","KYMR","IE00B894F039.SGD","BK4533","LU0006306889.USD","LU2089984988.USD","LU0320765059.SGD","LU1280957306.USD","SG9999014898.SGD","LU2237443465.HKD","LU0820561909.HKD","LU0238689110.USD","LU1989771016.USD","LU1720051017.SGD","LU1868837136.USD","BK4139"],"gpt_icon":1},{"id":"2517436994","title":"Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Kymera Therapeutics (KYMR) and Anika Therapeutics (ANIK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517436994","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517436994?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 22:10","pubTimestamp":1741356626,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Myomo (MYO – Research Report), Kymera Therapeutics (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-myomo-myo-kymera-therapeutics-kymr-and-anika-therapeutics-anik?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-myomo-myo-kymera-therapeutics-kymr-and-anika-therapeutics-anik?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANIK","BK4082","MYO","BK4137","KYMR","HCSG"],"gpt_icon":0},{"id":"2516645916","title":"Kymera Therapeutics Grants Performance Stock Units to Executives","url":"https://stock-news.laohu8.com/highlight/detail?id=2516645916","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516645916?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 06:03","pubTimestamp":1741039396,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics ( ($KYMR) ) has shared an update. On March 3, 2025, Kymera Therapeutics’ Board and Compensation Committee approved the grant of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kymera-therapeutics-grants-performance-stock-units-to-executives?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kymera-therapeutics-grants-performance-stock-units-to-executives?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYMR","LENZ","BK4139"],"gpt_icon":0},{"id":"2516586714","title":"Kymera Therapeutics’ Earnings Call Highlights Progress and Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2516586714","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516586714?lang=en_us&edition=full_marsco","pubTime":"2025-03-01 08:29","pubTimestamp":1740788993,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. (($KYMR)) has held its Q4 earnings call. Read on for the main highlights of the call. Kymera Therapeutics’ recent earning...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kymera-therapeutics-earnings-call-highlights-progress-and-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kymera-therapeutics-earnings-call-highlights-progress-and-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","KYMR","PRGS"],"gpt_icon":0},{"id":"2516130552","title":"Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2516130552","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516130552?lang=en_us&edition=full_marsco","pubTime":"2025-03-01 02:12","pubTimestamp":1740766320,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. KYMR reported a fourth-quarter 2024 loss of 88 cents per share, wider than the Zacks Consensus Estimate of a loss of 76 cents. In the year-ago quarter, Kymera reported a loss of 25 cents per share.The year-over-year deterioration was due to lower collaboration revenues and higher operating expenses.Collaboration revenues totaled $7.4 million, which missed the Zacks Consensus Estimate of $13 million.In the year-ago quarter, Kymera earned collaboration revenues of $47.9 million due to the recognition of milestone payments related to the advancement of KT-474 into phase II testing under its collaboration with pharma bigwig Sanofi SNY.Shares of KYMR have lost 30.1% year to date compared with the industry’s decline of 8%.In October, Kymera initiated the phase I study on KT-621 in healthy volunteers. KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6.Kymera intends to advance KT-295, an investigational, first-in-class, once daily, oral ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymeras-q4-loss-wider-expected-181200761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BMRN","LU1585245621.USD","LU1839511570.USD","LU0320765992.SGD","IE00B3T34201.USD","BK4588","LU0889565916.HKD","LU2087621335.USD","BK4566","BK4585","IE00BFXG1179.USD","BK4550","IE00BKVL7J92.USD","LU1571399168.USD","LU1066051498.USD","LU2089984988.USD","GILD","BK4578","LU2468319806.SGD","LU1430594728.SGD","BK4583","BK4007","BK4532","LU0058720904.USD","BK4568","IE00BZ1G4Q59.USD","LU0109394709.USD","LU0234570918.USD","LU1066053197.SGD","IE00B19Z3B42.SGD","IE0002270589.USD","IE00B19Z3581.USD","SNY","LU0289739699.SGD","IE00B7SZLL34.SGD","IE00BSNM7G36.USD","BK4139","KYMR"],"gpt_icon":0},{"id":"2514214303","title":"Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (LMAT), Dyne Therapeutics (DYN) and Kymera Therapeutics (KYMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514214303","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514214303?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 21:20","pubTimestamp":1740748816,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lemaitre Vascular (LMAT – Research Report), Dyne Therapeutics (DY...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-lemaitre-vascular-lmat-dyne-therapeutics-dyn-and-kymera-therapeutics-kymr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-lemaitre-vascular-lmat-dyne-therapeutics-dyn-and-kymera-therapeutics-kymr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4588","DYN","HCSG","LMAT","BK4505","BK4585","BK4082","KYMR","BK4139"],"gpt_icon":0},{"id":"2514432866","title":"Kymera Therapeutics: Buy Rating Affirmed Amid Promising STAT6 Program Developments and Adjusted Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2514432866","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514432866?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 19:40","pubTimestamp":1740742819,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on KYMR stock, giving a Buy rating yesterday. Andrew Fein has given his Buy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/kymera-therapeutics-buy-rating-affirmed-amid-promising-stat6-program-developments-and-adjusted-price-target?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/kymera-therapeutics-buy-rating-affirmed-amid-promising-stat6-program-developments-and-adjusted-price-target?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYMR","LENZ"],"gpt_icon":0},{"id":"2514642323","title":"We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2514642323","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514642323?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 19:36","pubTimestamp":1740742599,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?So, the natural question for Kymera Therapeutics  shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/were-not-very-worried-kymera-113639468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVIW.SI","TSYW.SI","LU2095319765.USD","BK4588",".IXIC","LU2210149790.SGD","LU2210150020.SGD","QID","IE00BKPKM429.USD","BK4112","IE00B64PRP62.GBP","MNQmain","IE00BGHQF748.EUR","USAW.SI","BK4139","NDAQ","SQQQ","PSQ","IE00B3QW5Z07.USD","QLD","BK4585","NQmain","TQQQ","USJW.SI","KYMR"],"gpt_icon":1},{"id":"2514349969","title":"Kymera Therapeutics: Promising Developments and Strategic Positioning Make It a Compelling Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2514349969","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514349969?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 17:57","pubTimestamp":1740736673,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics (KYMR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Derek Archil...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/kymera-therapeutics-promising-developments-and-strategic-positioning-make-it-a-compelling-buy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/kymera-therapeutics-promising-developments-and-strategic-positioning-make-it-a-compelling-buy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYMR","LENZ","BK4139"],"gpt_icon":0},{"id":"2514134303","title":"Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2514134303","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514134303?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 15:15","pubTimestamp":1740726959,"startTime":"0","endTime":"0","summary":"R&D Expenses: $71.8 million, including $6.8 million in non-cash stock-based compensation.Adjusted Cash R&D Spend: $65 million, a 23% increase from the previous quarter.G&A Expenses: $16.3 million, including $7 million in non-cash stock-based compensation.Adjusted Cash G&A Spend: $9.3 million, a 13% increase from the previous quarter.Cash Balance: $851 million, providing a runway into mid-2027.GuruFocus has detected 3 Warning Signs with KYMR.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Kymera Therapeutics Inc  is on track to report significant clinical data in 2025, including Phase I data for KT-621 and advancing KT-295 into the clinic.Kymera Therapeutics Inc  has high R&D expenses, with a 23% sequential increase in adjusted cash R&D spend from the third quarter.A: Jared Gollob, Chief Medical Officer, explained that prior dupilumab trials showed clear impacts on Th2 biomarkers and clinical endpoints like EASI and pruritus NRS within","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymera-therapeutics-inc-kymr-q4-071559722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNY","KYMR"],"gpt_icon":0},{"id":"2514395309","title":"Kymera Therapeutics Reports 2024 Financial Results and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2514395309","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514395309?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 12:16","pubTimestamp":1740716207,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. ( ($KYMR) ) has released its Q4 earnings. Here is a breakdown of the information Kymera Therapeutics, Inc. presented to i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kymera-therapeutics-reports-2024-financial-results-and-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kymera-therapeutics-reports-2024-financial-results-and-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYMR","LENZ","BK4139","PRGS","BK4097","LU2065732104.USD"],"gpt_icon":0},{"id":"2514339287","title":"Kymera Therapeutics (KYMR) Receives a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2514339287","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514339287?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 02:45","pubTimestamp":1740681920,"startTime":"0","endTime":"0","summary":"In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report). The company’s shares ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/kymera-therapeutics-kymr-receives-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/kymera-therapeutics-kymr-receives-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYMR","BK4585","BK4139","COWN","BK4566","BK4207","BK4127","TD"],"gpt_icon":0},{"id":"2514938717","title":"Kymera Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2514938717","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514938717?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 00:39","pubTimestamp":1740674394,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryKymera Therapeutics Inc KYMR.OQ reported a quarterly adjusted loss of 88 cents per share for the quarter end","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL5N3PI2KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR"],"gpt_icon":0},{"id":"1118306033","title":"Stock Track | Kymera Therapeutics Plummets 7.27% in Early Trading on Disappointing Q4 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1118306033","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118306033?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 23:10","pubTimestamp":1740669006,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc.  stock plunged 7.27% in early Thursday trading following the release of its disappointing fourth-quarter results. The biopharmaceutical company reported a wider net loss and lower collaboration revenue compared to the year-ago period, missing analyst estimates.For the quarter ended December 31, 2024, Kymera Therapeutics posted a net loss of $0.88 per diluted share, significantly worse than the $0.25 loss in the same period a year earlier. The company's collaboration rev","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Kymera Therapeutics Plummets 7.27% in Early Trading on Disappointing Q4 Results","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["KYMR"],"gpt_icon":0},{"id":"2514306800","title":"Kymera Therapeutics Q4 Net Loss Widens, Collaboration Revenue Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2514306800","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514306800?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 21:53","pubTimestamp":1740664407,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics  reported a Q4 net loss Thursday of $0.88 per diluted share, wider than the loss of $0.25 a year earlier.Analysts polled by FactSet expected a loss of $0.86.Collaboration revenue for the quarter ended Dec. 31 was $7.4 million, down from $47.9 million a year earlier.Analysts surveyed by FactSet expected $14.4 million.Kymera said that as of Dec. 31, it had about $851 million in cash, cash equivalents, and investments, which it expects to provide a cash runway into mid-2027.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","KYMR"],"gpt_icon":0},{"id":"2514386220","title":"Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2514386220","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514386220?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 21:15","pubTimestamp":1740662109,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc.  came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -15.79%. A quarter ago, it was expected that this company would post a loss of $0.83 per share when it actually produced a loss of $0.82, delivering a surprise of 1.20%.Kymera Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $7.39 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 43.50%. This compares to year-ago revenues of $47.88 million. The company has topped consensus revenue estimates just once over the last four quarters.Kymera Therapeutics shares have lost about 12.1% since the beginning of the year versus the S&P 500's gain of 1.3%.While Kymera Therapeutics has underperformed the market so far this ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymera-therapeutics-inc-kymr-reports-131509591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KYMR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kymeratx.com","stockEarnings":[{"period":"1week","weight":-0.2069},{"period":"1month","weight":-0.1951},{"period":"3month","weight":-0.3727},{"period":"6month","weight":-0.4187},{"period":"1year","weight":-0.3598},{"period":"ytd","weight":-0.3727}],"compareEarnings":[{"period":"1week","weight":-0.0252},{"period":"1month","weight":-0.0559},{"period":"3month","weight":-0.0428},{"period":"6month","weight":-0.0121},{"period":"1year","weight":0.0743},{"period":"ytd","weight":-0.0428}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.085982},{"month":2,"riseRate":0.2,"avgChangeRate":-0.068972},{"month":3,"riseRate":0.2,"avgChangeRate":-0.073393},{"month":4,"riseRate":0.4,"avgChangeRate":-0.052857},{"month":5,"riseRate":0.25,"avgChangeRate":-0.150138},{"month":6,"riseRate":0.5,"avgChangeRate":0.024718},{"month":7,"riseRate":0.75,"avgChangeRate":0.214781},{"month":8,"riseRate":0.75,"avgChangeRate":0.05865},{"month":9,"riseRate":0.2,"avgChangeRate":-0.112915},{"month":10,"riseRate":0.6,"avgChangeRate":0.065},{"month":11,"riseRate":0.6,"avgChangeRate":0.197535},{"month":12,"riseRate":0.6,"avgChangeRate":0.083852}],"exchange":"NASDAQ","name":"Kymera Therapeutics, Inc.","nameEN":"Kymera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kymera Therapeutics, Inc.(KYMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kymera Therapeutics, Inc.,KYMR,Kymera Therapeutics, Inc.股票,Kymera Therapeutics, Inc.股票老虎,Kymera Therapeutics, Inc.股票老虎国际,Kymera Therapeutics, Inc.行情,Kymera Therapeutics, Inc.股票行情,Kymera Therapeutics, Inc.股价,Kymera Therapeutics, Inc.股市,Kymera Therapeutics, Inc.股票价格,Kymera Therapeutics, Inc.股票交易,Kymera Therapeutics, Inc.股票购买,Kymera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kymera Therapeutics, Inc.(KYMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction